Status:
COMPLETED
Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Sarcoma, Soft Tissue
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Complete resection is still the only curative treatment option in patients with soft tissue sarcoma (STS). Patients with a non-resectable STS have a dismal prognosis even without evidence of metastati...
Eligibility Criteria
Inclusion
- Histologically confirmed STS with locally advanced non-resectable disease
- Metastatic disease is allowed in case of solitary resectable metastases
- Grading according to Coindre \> II°
- Measurable tumor lesions
- Age \> 18 through 65 years
- Karnofsky status \> 70 %
- Written informed consent
Exclusion
- Prior chemotherapy
- Intercurrent disease interfering with the adequate administration of study medication including severe psychological disease
- Insufficient liver-, renal or bone marrow function
- Evidence of pregnancy
- Treatment within another clinical trial
- Uncontrolled viral Infections (HIV,HBV, HCV)
- other malignancies
Key Trial Info
Start Date :
February 1 1999
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00204646
Start Date
February 1 1999
End Date
December 1 2006
Last Update
April 20 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Center II, University of Tuebingen
Tübingen, Germany, 72076